Objectives
• Emphasize points of consensus on the impact of prevention on the populations we serve.
• Promote bidirectional communication on the issues – we can learn from each other
• Recognize our differences – but concentrate on the bigger issues

Top 10 Take Home Messages:
• Adults 40–75 years of age being evaluated for CVD prevention should undergo 10-year atherosclerotic cardiovascular disease risk estimation.
• Clinician–patient risk discussion before starting pharmacological therapy, such as antihypertensive therapy, statin, or aspirin
• Risk-enhancing factors and calcium scoring may help guide decisions about preventive interventions in select individuals

• Adults 40–75 years of age being evaluated for CVD prevention should undergo 10-year atherosclerotic cardiovascular disease risk estimation.
• Clinician–patient risk discussion before starting pharmacological
therapy, such as antihypertensive therapy, statin, or aspirin
• Risk-enhancing factors and calcium scoring may help guide decisions about preventive interventions in select individuals

• Adults 40–75 years of age being evaluated for CVD prevention should undergo 10-year atherosclerotic cardiovascular disease risk estimation.
• Clinician–patient risk discussion before starting pharmacological therapy, such as antihypertensive therapy, statin, or aspirin
• Risk-enhancing factors and calcium scoring may help guide decisions about preventive interventions in select individuals